Who are Newleos Therapeutics's investors?

Newleos Therapeutics's investors include DCVC (Data Collective), DCVC Bio, Longwood Fund, Novo Holdings.

How much funding has Newleos Therapeutics raised?

Newleos Therapeutics has disclosed $93.4M raised across 1 round.

Where is Newleos Therapeutics headquartered?

Newleos Therapeutics is headquartered in Boston, US.

Newleos Therapeutics

Boston, US · Founded 2024 · Delaware corporation · 29 employees on LinkedIn · 6 known investors

Find your way into Newleos Therapeutics

474 people in our graph share verified history with the Newleos Therapeutics team — schools, employers, funds. One of them is your warm intro.

Glenn Shortunlockedknows John McCabe · together at Flex Pharma (overlapped)

knows the team · via Oncorus

knows the team · via Ziopharm Oncology

knows the team · via DEM Biopharma, Inc.

knows the team · via ARIAD Pharmaceuticals, Inc.

×3knows the team · via Longwood Fund

Biotech

Founders & leadership

David Donabedian ExecutivePartner, NewCo Formation at Longwood Fund

Robert Hadfield ExecutiveGeneral Counsel & Operating Partner at Longwood Fund

John McCabe ExecutivePortfolio Company CFO & COO at Longwood Fund

Board

Christoph WestphalBoard directorCo-Founder & General Partner at Longwood Fund

Ming CheahMember Board of DirectorsAdvisor

Raymond CamahortBoard directorPrincipal at Novo Holdings

Investors · 6

DCVC (Data Collective)listed by DCVC (Data Collective)Palo Alto · $5M – $25M

How we know: DCVC (Data Collective)'s portfolio page · Not right? Tell us

DCVC Biolisted by DCVC BioPalo Alto

How we know: DCVC Bio's portfolio page · gunder.com · Not right? Tell us

Longwood FundreportedBostonvia Christoph Westphal · board

How we know: board seat on SEC Form D · funding news · gunder.com · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: funding news · gunder.com · Not right? Tell us

Also in the syndicate · 2

Arkin Bio CapitalGoldman Sachs Alternativeslead

Reported raises · per SEC filings

Form D private placements

$93.4M disclosed across 1 round · 2025

▶$93.4MraisedFeb 2025 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David DonabedianExecutive Officer, Director
Robert HadfieldExecutive Officer
Christoph WestphalDirector
Ming CheahDirector
Raymond CamahortDirector
John McCabeExecutive Officer

Offering amount: $93.4M
Amount sold: $93.4M
First sale: Feb 2025
Incorporated: Corporation, Delaware, 2024
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Newleos Therapeutics went on to found or lead other companies.

David DonabedianExecutive Officer, DirectorFounded Axial Biotherapeutics Rohan PalekarChair Board of DirectorsFounded 89bio (NASDAQ: ETNB)

Frequently asked questions

Who are Newleos Therapeutics's investors?: Newleos Therapeutics's investors include DCVC (Data Collective), DCVC Bio, Longwood Fund, Novo Holdings.
How much funding has Newleos Therapeutics raised?: Newleos Therapeutics has disclosed $93.4M raised across 1 round.
Where is Newleos Therapeutics headquartered?: Newleos Therapeutics is headquartered in Boston, US.